CN102861317B - 沙门氏菌鞭毛蛋白衍生物在制备防治炎症性肠病药物中的应用 - Google Patents
沙门氏菌鞭毛蛋白衍生物在制备防治炎症性肠病药物中的应用 Download PDFInfo
- Publication number
- CN102861317B CN102861317B CN201210018080.4A CN201210018080A CN102861317B CN 102861317 B CN102861317 B CN 102861317B CN 201210018080 A CN201210018080 A CN 201210018080A CN 102861317 B CN102861317 B CN 102861317B
- Authority
- CN
- China
- Prior art keywords
- czlc331
- derivant
- salmonella flagellin
- albumen
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010040721 Flagellin Proteins 0.000 title claims abstract description 76
- 241000607142 Salmonella Species 0.000 title claims abstract description 76
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims description 20
- 208000022559 Inflammatory bowel disease Diseases 0.000 title abstract description 13
- 229940079593 drug Drugs 0.000 title abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 56
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 33
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 33
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 12
- 241001597008 Nomeidae Species 0.000 claims description 63
- 239000007924 injection Substances 0.000 claims description 23
- 238000002347 injection Methods 0.000 claims description 23
- 230000009465 prokaryotic expression Effects 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 241000588724 Escherichia coli Species 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 17
- 230000026683 transduction Effects 0.000 claims description 14
- 238000010361 transduction Methods 0.000 claims description 14
- 101710149951 Protein Tat Proteins 0.000 claims description 13
- 150000001413 amino acids Chemical group 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 241000792859 Enema Species 0.000 claims description 5
- 239000007920 enema Substances 0.000 claims description 5
- 229940095399 enema Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 238000010276 construction Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 229920003081 Povidone K 30 Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 230000002265 prevention Effects 0.000 abstract description 16
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 230000009471 action Effects 0.000 abstract description 5
- 208000011231 Crohn disease Diseases 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 46
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 31
- 210000001072 colon Anatomy 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 24
- 230000002757 inflammatory effect Effects 0.000 description 19
- 102000002689 Toll-like receptor Human genes 0.000 description 14
- 108020000411 Toll-like receptor Proteins 0.000 description 14
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 13
- 210000004400 mucous membrane Anatomy 0.000 description 13
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 13
- 229960001940 sulfasalazine Drugs 0.000 description 13
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 208000035861 hematochezia Diseases 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 208000025865 Ulcer Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 206010020565 Hyperaemia Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 210000002175 goblet cell Anatomy 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 240000000220 Panda oleosa Species 0.000 description 5
- 235000016496 Panda oleosa Nutrition 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 238000012827 research and development Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 208000019155 Radiation injury Diseases 0.000 description 3
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000000680 avirulence Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 201000010000 Agranulocytosis Diseases 0.000 description 2
- 108010079458 CBLB502 Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 241001269238 Data Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010018687 Granulocytopenia Diseases 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 230000003471 anti-radiation Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 208000037902 enteropathy Diseases 0.000 description 2
- 229950009493 entolimod Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 239000000718 radiation-protective agent Substances 0.000 description 2
- 230000004223 radioprotective effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 108010064245 urinary gonadotropin fragment Proteins 0.000 description 2
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010028140 Mucous stools Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- -1 absorption carrier Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005261 decarburization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210018080.4A CN102861317B (zh) | 2011-07-05 | 2012-01-19 | 沙门氏菌鞭毛蛋白衍生物在制备防治炎症性肠病药物中的应用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110186065 | 2011-07-05 | ||
| CN201110186065.6 | 2011-07-05 | ||
| CN201210018080.4A CN102861317B (zh) | 2011-07-05 | 2012-01-19 | 沙门氏菌鞭毛蛋白衍生物在制备防治炎症性肠病药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102861317A CN102861317A (zh) | 2013-01-09 |
| CN102861317B true CN102861317B (zh) | 2014-07-02 |
Family
ID=47436474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210018080.4A Expired - Fee Related CN102861317B (zh) | 2011-07-05 | 2012-01-19 | 沙门氏菌鞭毛蛋白衍生物在制备防治炎症性肠病药物中的应用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9259453B2 (enExample) |
| EP (1) | EP2730287B1 (enExample) |
| JP (1) | JP5876930B2 (enExample) |
| KR (1) | KR101814558B1 (enExample) |
| CN (1) | CN102861317B (enExample) |
| AU (1) | AU2012278744B2 (enExample) |
| CA (1) | CA2840924A1 (enExample) |
| WO (1) | WO2013004069A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11273198B2 (en) | 2017-05-04 | 2022-03-15 | Second Genome, Inc. | Proteins for the treatment of epithelial barrier function disorders |
| US10402165B2 (en) | 2017-08-30 | 2019-09-03 | Gsi Technology Inc. | Concurrent multi-bit adder |
| CN108159397A (zh) * | 2018-02-28 | 2018-06-15 | 中南大学湘雅三医院 | 一种肠罗斯氏菌重组鞭毛蛋白在制备防治炎症性肠病药物中的应用 |
| CN108404113A (zh) * | 2018-05-16 | 2018-08-17 | 中国人民解放军军事科学院军事医学研究院 | 用于抗辐射损伤的口服辐抗肽药物组合物 |
| US20220218786A1 (en) * | 2019-03-28 | 2022-07-14 | The Catholic University Of Korea Industry-Academic Cooperation Foundation | Composition for preventing or treating graft-versus-host disease comprising tlr5 agonist derived from flagellin as effective component |
| CN110420317B (zh) * | 2019-07-25 | 2022-11-22 | 中国人民解放军军事科学院军事医学研究院 | Cblb502蛋白在防治创伤后应激障碍中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050073865A (ko) * | 2004-01-12 | 2005-07-18 | 대한민국(전남대학교총장) | 비브리오 패혈증균 편모 구성인자 플라젤린을유효성분으로 함유하는 백신 보조제 |
| JP5285278B2 (ja) * | 2004-12-22 | 2013-09-11 | クリーブランド クリニック ファウンデイション | フラゲリン関連ポリペプチドおよびその使用 |
| AR052195A1 (es) * | 2005-01-19 | 2007-03-07 | Vaxinnate Corp | Composiciones de patrones moleculares asociados a patogenos en metodos de uso |
| CA2531261A1 (en) * | 2005-12-21 | 2007-06-21 | Institut Pasteur | Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria |
| JP2011519834A (ja) * | 2008-04-25 | 2011-07-14 | インスティチュート フォー システムズ バイオロジー | フラジェリンポリペプチドワクチン |
| CN101411872A (zh) * | 2008-11-25 | 2009-04-22 | 中国科学院武汉病毒研究所 | 预防龋齿的疫苗试剂盒及其使用方法 |
-
2012
- 2012-01-19 CN CN201210018080.4A patent/CN102861317B/zh not_active Expired - Fee Related
- 2012-01-19 KR KR1020147002932A patent/KR101814558B1/ko not_active Expired - Fee Related
- 2012-01-19 CA CA2840924A patent/CA2840924A1/en not_active Abandoned
- 2012-01-19 EP EP12807820.1A patent/EP2730287B1/en not_active Not-in-force
- 2012-01-19 US US14/131,050 patent/US9259453B2/en not_active Expired - Fee Related
- 2012-01-19 JP JP2014517394A patent/JP5876930B2/ja not_active Expired - Fee Related
- 2012-01-19 WO PCT/CN2012/000097 patent/WO2013004069A1/zh not_active Ceased
- 2012-01-19 AU AU2012278744A patent/AU2012278744B2/en not_active Ceased
-
2015
- 2015-11-13 US US14/940,648 patent/US9630999B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140054018A (ko) | 2014-05-08 |
| EP2730287B1 (en) | 2018-02-28 |
| JP2014522819A (ja) | 2014-09-08 |
| US9630999B2 (en) | 2017-04-25 |
| NZ619871A (en) | 2016-02-26 |
| US20140248348A1 (en) | 2014-09-04 |
| WO2013004069A1 (zh) | 2013-01-10 |
| EP2730287A4 (en) | 2015-03-18 |
| AU2012278744A1 (en) | 2014-02-20 |
| US20160060305A1 (en) | 2016-03-03 |
| KR101814558B1 (ko) | 2018-01-30 |
| EP2730287A1 (en) | 2014-05-14 |
| JP5876930B2 (ja) | 2016-03-02 |
| US9259453B2 (en) | 2016-02-16 |
| CN102861317A (zh) | 2013-01-09 |
| CA2840924A1 (en) | 2013-01-10 |
| AU2012278744B2 (en) | 2016-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861317A (zh) | 沙门氏菌鞭毛蛋白衍生物在制备防治炎症性肠病药物中的应用 | |
| WO2021204170A1 (zh) | 一种中华冀土鳖虫来源的具有降血脂功能的活性肽及其制备方法和应用 | |
| Szczepaniak et al. | The role of kappa opioid receptors in immune system–an overview | |
| WO2017155234A1 (ko) | 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도 | |
| CN103275187A (zh) | 一种镇痛肽fi及其基因和应用 | |
| KR101986774B1 (ko) | 과면역 반응에 의해 유발되는 염증성 질환 치료용 조성물 | |
| WO2017155233A1 (ko) | 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도 | |
| CN101822670B (zh) | 小檗碱在制备防治类风湿关节炎的药物中的应用 | |
| CN102579559B (zh) | 一种龙须藤乙酸乙酯提取物、正丁醇提取物及其制备方法和用途 | |
| EP2653477B1 (en) | Scorpion active peptides and preparation methods and applications thereof | |
| EP4047007B1 (en) | Peptide and use thereof in preparation of drug for treating inflammatory diseases and pain | |
| CN102784157B (zh) | 纤细薯蓣皂苷的用途以及含有纤细薯蓣皂苷的药物组合物 | |
| CN103251667B (zh) | 土木香总倍半萜内酯在制备治疗类风湿性关节炎药物中的应用 | |
| CN102579558B (zh) | 龙须藤总黄酮在制备治疗类风湿性关节炎的药物中的用途 | |
| CN102988422A (zh) | 美洲大蠊纳米提取物及其制备方法 | |
| CN117843756A (zh) | 一种角蛋白yk93-9、制法和其药物组合物与用途 | |
| CN110420317B (zh) | Cblb502蛋白在防治创伤后应激障碍中的应用 | |
| NZ619871B2 (en) | Use of salmonella flagellin derivative in preparation of drug for preventing and treating inflammatory bowel diseases | |
| CN103012597B (zh) | 用于治疗骨质疏松症和止痛的OGP-CTx融合蛋白及编码该融合蛋白的核酸 | |
| US5948442A (en) | Stimulating ENTEROGENIN compositions and methods for their isolation and use | |
| CN121592743A (zh) | 一种制备海马小肽组合物的方法、组合物及应用 | |
| CN106539816A (zh) | 环二核苷酸在防治多发性硬化症中的应用 | |
| JP2928608B2 (ja) | インスリン依存型糖尿病予防または治療剤 | |
| CN118184736A (zh) | 活性肽、含有活性肽的组合物及其应用 | |
| CN104840746B (zh) | 一种具有抗肺癌活性的中药组合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140702 Termination date: 20190119 |